Photo of Shane Stecklein taken from www.kumc.edu
Nov 27, 2023, 19:13
Shane Stecklein: The clinical and biomarker results from our phase II NeoPACT study for triple negative breast cancer
Shane Stecklein, Breast, Hematology, Radiation Oncology and Cancer Biologist at KU Cancer Center, made the following post on Twitter:
“Excited to share the clinical and biomarker results from our phase II NeoPACT study of neoadjuvant anthracycline-free chemoimmunotherapy for triple negative breast cancer in Jama Oncology. This regimen is the experimental arm in ongoing
SWOG Cancer Research Network S2212 (SCARLET).”
For details click here.
Source: Shane Stecklein/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 09:28
Nov 21, 2024, 09:23
Nov 21, 2024, 09:04
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27